Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

CK-0045 induced exposure-dependent reductions in body weight and improvement of key metabolic parameters in participants with obesity Data support advancement of CK-0045 into Phase 2 proof-of-concept studies in individuals with type 2 diabetes and/or obesity COPENHAGEN, Denmark, July 23,…